Literature DB >> 31235488

Responsible use of rifampin for the treatment of latent tuberculosis infection.

Jane Batt1, Kamran Khan2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31235488      PMCID: PMC6592804          DOI: 10.1503/cmaj.190081

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

Review 1.  Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review.

Authors:  S R Mase; A Ramsay; V Ng; M Henry; P C Hopewell; J Cunningham; R Urbanczik; M D Perkins; M A Aziz; M Pai
Journal:  Int J Tuberc Lung Dis       Date:  2007-05       Impact factor: 2.373

2.  Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.

Authors:  Dick Menzies; Menonli Adjobimey; Rovina Ruslami; Anete Trajman; Oumou Sow; Heejin Kim; Joseph Obeng Baah; Guy B Marks; Richard Long; Vernon Hoeppner; Kevin Elwood; Hamdan Al-Jahdali; Martin Gninafon; Lika Apriani; Raspati C Koesoemadinata; Afranio Kritski; Valeria Rolla; Boubacar Bah; Alioune Camara; Isaac Boakye; Victoria J Cook; Hazel Goldberg; Chantal Valiquette; Karen Hornby; Marie-Josée Dion; Pei-Zhi Li; Philip C Hill; Kevin Schwartzman; Andrea Benedetti
Journal:  N Engl J Med       Date:  2018-08-02       Impact factor: 91.245

3.  Three months of rifapentine and isoniazid for latent tuberculosis infection.

Authors:  Timothy R Sterling; M Elsa Villarino; Andrey S Borisov; Nong Shang; Fred Gordin; Erin Bliven-Sizemore; Judith Hackman; Carol Dukes Hamilton; Dick Menzies; Amy Kerrigan; Stephen E Weis; Marc Weiner; Diane Wing; Marcus B Conde; Lorna Bozeman; C Robert Horsburgh; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

Review 4.  Sputum induction for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis.

Authors:  Y Gonzalez-Angulo; C S Wiysonge; H Geldenhuys; W Hanekom; H Mahomed; G Hussey; M Hatherill
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-18       Impact factor: 3.267

5.  Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.

Authors:  Clare L van Halsema; Katherine L Fielding; Violet N Chihota; Elizabeth C Russell; James J C Lewis; Gavin J Churchyard; Alison D Grant
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

Review 6.  Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis.

Authors:  S den Boon; A Matteelli; H Getahun
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

7.  High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening.

Authors:  Tolu Oni; Rachael Burke; Relebohile Tsekela; Nonzwakazi Bangani; Ronnett Seldon; Hannah P Gideon; Kathryn Wood; Katalin A Wilkinson; Tom H M Ottenhoff; Robert J Wilkinson
Journal:  Thorax       Date:  2011-05-31       Impact factor: 9.139

Review 8.  Towards tuberculosis elimination: an action framework for low-incidence countries.

Authors:  Knut Lönnroth; Giovanni Battista Migliori; Ibrahim Abubakar; Lia D'Ambrosio; Gerard de Vries; Roland Diel; Paul Douglas; Dennis Falzon; Marc-Andre Gaudreau; Delia Goletti; Edilberto R González Ochoa; Philip LoBue; Alberto Matteelli; Howard Njoo; Ivan Solovic; Alistair Story; Tamara Tayeb; Marieke J van der Werf; Diana Weil; Jean-Pierre Zellweger; Mohamed Abdel Aziz; Mohamed R M Al Lawati; Stefano Aliberti; Wouter Arrazola de Oñate; Draurio Barreira; Vineet Bhatia; Francesco Blasi; Amy Bloom; Judith Bruchfeld; Francesco Castelli; Rosella Centis; Daniel Chemtob; Daniela M Cirillo; Alberto Colorado; Andrei Dadu; Ulf R Dahle; Laura De Paoli; Hannah M Dias; Raquel Duarte; Lanfranco Fattorini; Mina Gaga; Haileyesus Getahun; Philippe Glaziou; Lasha Goguadze; Mirtha Del Granado; Walter Haas; Asko Järvinen; Geun-Yong Kwon; Davide Mosca; Payam Nahid; Nobuyuki Nishikiori; Isabel Noguer; Joan O'Donnell; Analita Pace-Asciak; Maria G Pompa; Gilda G Popescu; Carlos Robalo Cordeiro; Karin Rønning; Morten Ruhwald; Jean-Paul Sculier; Aleksandar Simunović; Alison Smith-Palmer; Giovanni Sotgiu; Giorgia Sulis; Carlos A Torres-Duque; Kazunori Umeki; Mukund Uplekar; Catharina van Weezenbeek; Tuula Vasankari; Robert J Vitillo; Constantia Voniatis; Maryse Wanlin; Mario C Raviglione
Journal:  Eur Respir J       Date:  2015-04       Impact factor: 16.671

9.  Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.

Authors:  Suzanne M Marks; Jennifer Flood; Barbara Seaworth; Yael Hirsch-Moverman; Lori Armstrong; Sundari Mase; Katya Salcedo; Peter Oh; Edward A Graviss; Paul W Colson; Lisa Armitige; Manuel Revuelta; Kathryn Sheeran
Journal:  Emerg Infect Dis       Date:  2014-05       Impact factor: 6.883

10.  Direct and indirect costs of tuberculosis among immigrant patients in the Netherlands.

Authors:  Sandra V Kik; Sandra P J Olthof; Jonie T N de Vries; Dick Menzies; Naomi Kincler; Joke van Loenhout-Rooyakkers; Conny Burdo; Suzanne Verver
Journal:  BMC Public Health       Date:  2009-08-05       Impact factor: 3.295

  10 in total
  3 in total

1.  Responsible use of rifampin in Canada is threatened by irresponsible shortages.

Authors:  Adam R Houston; Ryan Cooper; Faiz Ahmad Khan
Journal:  CMAJ       Date:  2019-10-15       Impact factor: 8.262

2.  No evidence of increased risk of acquired rifampin resistance.

Authors:  Dick Menzies; Victoria Cook; Richard Long; Rovina Ruslami
Journal:  CMAJ       Date:  2019-11-25       Impact factor: 8.262

3.  Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.

Authors:  Emily A Kendall; Hamidah Hussain; Amber Kunkel; Rachel W Kubiak; Anete Trajman; Richard Menzies; Paul K Drain
Journal:  BMC Med       Date:  2021-12-14       Impact factor: 11.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.